Literature DB >> 7743336

Release of endothelin in relation to tumor necrosis factor-alpha in porcine Pseudomonas aeruginosa-induced septic shock.

J J Han1, A Windsor, D H Drenning, S Leeper-Woodford, P G Mullen, D E Bechard, H J Sugerman, A A Fowler.   

Abstract

Septic shock is characterized by surges of tumor necrosis factor-alpha (TNF-alpha) along with myocardial dysfunction and systemic hypotension. TNF-alpha promotes the release of immunoreactive endothelin (ET). Because TNF-alpha is elevated in septic shock, we hypothesized that elevated levels of endothelin can contribute to cardiac dysfunction and hypotension. We infused live Pseudomonas aeruginosa into anesthetized, hemodynamically monitored young swine and measured ET and TNF-alpha. Septic swine developed systemic arterial hypotension and had significantly elevated TNF-alpha (4.15 +/- .41 U/ml at 1 h versus .40 +/- .13 U/ml at time zero) compared to control animals. ET levels were significantly elevated at 4 h (52.38 +/- 12.88 pg/ml vs. 10.45 +/- 1.82 pg/ml at time zero) and correlated negatively with the decline in cardiac output. We then passively immunized swine using anti TNF-alpha prior to the induction of sepsis to examine if TNF played a central role in the release ET. The anti TNF-alpha effectively removed circulating TNF-alpha bioactivity in septic animals. Anti-TNF-alpha-treated animals did not develop significant systemic arterial hypotension and had significant attenuation in endothelin (19.01 +/- 4.18 pg/ml at 4 h compared to 52.38 +/- 12.88 pg/ml in septic animals at 4 h) which correlated with preservation of cardiac output. TNF-alpha may cause cardiac dysfunction in sepsis syndrome through increased release of ET.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7743336     DOI: 10.1097/00024382-199405000-00004

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  The contribution of tumour necrosis factor-alpha and endothelin-1 to the increase of coronary resistance in hearts from rats treated with endotoxin.

Authors:  T Hohlfeld; P Klemm; C Thiemermann; T D Warner; K Schrör; J R Vane
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670.

Authors:  P Klemm; T D Warner; D Willis; A R Moore; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

3.  Haemodynamic effects of endothelin receptor antagonist, tezosentan, in tumour necrosis factor-alpha treated anaesthetized rats.

Authors:  Reza Tabrizchi; Carol Ann Ford
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-18       Impact factor: 3.000

4.  Attenuation of shock-induced inflammation in the rat liver depends on the time of TNF-alpha inhibition.

Authors:  C Bauer; W Roth; S Bahrami; I Marzi
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

5.  Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat.

Authors:  H Ruetten; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.